187 related articles for article (PubMed ID: 35802185)
21. Perioperative management of disease-modifying antirheumatic drugs and other immunomodulators.
Moreira PM; Correia AM; Cerqueira M; Gil MF
ARP Rheumatol; 2022 Oct; 1(ARP Rheumatology, nº3 2022):218-224. PubMed ID: 36057090
[TBL] [Abstract][Full Text] [Related]
22. [DMARD (disease-modifying antirheumatic drug) treatment in patients with former or current cancer].
Krüger K
Z Rheumatol; 2023 Apr; 82(3):206-211. PubMed ID: 36757415
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis.
Harigai M; Winthrop K; Takeuchi T; Hsieh TY; Chen YM; Smolen JS; Burmester G; Walls C; Wu WS; Dickson C; Liao R; Genovese MC
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098857
[TBL] [Abstract][Full Text] [Related]
24. [Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases].
Krüger K; Albrecht K; Rehart S; Scholz R;
Z Rheumatol; 2014 Feb; 73(1):77-84. PubMed ID: 24310229
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Song GG; Choi SJ; Lee YH
Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
[TBL] [Abstract][Full Text] [Related]
26. Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.
Welzel T; Winskill C; Zhang N; Woerner A; Pfister M
Pediatr Rheumatol Online J; 2021 Mar; 19(1):46. PubMed ID: 33766063
[TBL] [Abstract][Full Text] [Related]
27. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
[TBL] [Abstract][Full Text] [Related]
28. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Goodman SM; Springer B; Guyatt G; Abdel MP; Dasa V; George M; Gewurz-Singer O; Giles JT; Johnson B; Lee S; Mandl LA; Mont MA; Sculco P; Sporer S; Stryker L; Turgunbaev M; Brause B; Chen AF; Gililland J; Goodman M; Hurley-Rosenblatt A; Kirou K; Losina E; MacKenzie R; Michaud K; Mikuls T; Russell L; Sah A; Miller AS; Singh JA; Yates A
Arthritis Care Res (Hoboken); 2017 Aug; 69(8):1111-1124. PubMed ID: 28620917
[TBL] [Abstract][Full Text] [Related]
29. [Small molecules treatment in rheumatoid arthritis].
Verdon A; Lauper K
Rev Med Suisse; 2020 Mar; 16(685):477-480. PubMed ID: 32167248
[TBL] [Abstract][Full Text] [Related]
30. Delayed wound healing and postoperative surgical site infections in patients with rheumatoid arthritis treated with or without biological disease-modifying antirheumatic drugs.
Tada M; Inui K; Sugioka Y; Mamoto K; Okano T; Kinoshita T; Hidaka N; Koike T
Clin Rheumatol; 2016 Jun; 35(6):1475-81. PubMed ID: 27129711
[TBL] [Abstract][Full Text] [Related]
31. Perioperative management of disease-modifying antirheumatic drugs for patients undergoing elective spine surgery: a systematic review.
Mamaril-Davis JC; Aguilar-Salinas P; Avila MJ; Villatoro-Villar M; Dumont TM
Eur Spine J; 2022 Apr; 31(4):815-829. PubMed ID: 35132461
[TBL] [Abstract][Full Text] [Related]
32. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study.
George MD; Baker JF; Winthrop K; Alemao E; Chen L; Connolly S; Hsu JY; Simon TA; Wu Q; Xie F; Yang S; Curtis JR
Ann Intern Med; 2019 Jun; 170(12):825-836. PubMed ID: 31108503
[TBL] [Abstract][Full Text] [Related]
33. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
Fraenkel L; Bathon JM; England BR; St Clair EW; Arayssi T; Carandang K; Deane KD; Genovese M; Huston KK; Kerr G; Kremer J; Nakamura MC; Russell LA; Singh JA; Smith BJ; Sparks JA; Venkatachalam S; Weinblatt ME; Al-Gibbawi M; Baker JF; Barbour KE; Barton JL; Cappelli L; Chamseddine F; George M; Johnson SR; Kahale L; Karam BS; Khamis AM; Navarro-Millán I; Mirza R; Schwab P; Singh N; Turgunbaev M; Turner AS; Yaacoub S; Akl EA
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):924-939. PubMed ID: 34101387
[TBL] [Abstract][Full Text] [Related]
34. German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
Albrecht K; Krüger K; Wollenhaupt J; Alten R; Backhaus M; Baerwald C; Bolten W; Braun J; Burkhardt H; Burmester GR; Gaubitz M; Gause A; Gromnica-Ihle E; Kellner H; Kuipers J; Krause A; Lorenz HM; Manger B; Nüßlein H; Pott HG; Rubbert-Roth A; Schneider M; Specker C; Schulze-Koops H; Tony HP; Wassenberg S; Müller-Ladner U;
Rheumatol Int; 2014 Jan; 34(1):1-9. PubMed ID: 23942828
[TBL] [Abstract][Full Text] [Related]
35. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
Graudal N; Jürgens G
Arthritis Rheum; 2010 Oct; 62(10):2852-63. PubMed ID: 20560138
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Sung YK; Lee YH
J Clin Pharm Ther; 2021 Aug; 46(4):984-992. PubMed ID: 33600008
[TBL] [Abstract][Full Text] [Related]
37. The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy.
Kissin EY
Clin Ther; 2014 Jul; 36(7):1114-6. PubMed ID: 24996488
[TBL] [Abstract][Full Text] [Related]
38. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.
Sepriano A; Kerschbaumer A; Smolen JS; van der Heijde D; Dougados M; van Vollenhoven R; McInnes IB; Bijlsma JW; Burmester GR; de Wit M; Falzon L; Landewé R
Ann Rheum Dis; 2020 Jun; 79(6):760-770. PubMed ID: 32033941
[TBL] [Abstract][Full Text] [Related]
39. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
Decarriere G; Barnetche T; Combe B; Gaujoux-Viala C; Lukas C; Morel J; Daien C
Arthritis Care Res (Hoboken); 2021 Jun; 73(6):873-884. PubMed ID: 32216091
[TBL] [Abstract][Full Text] [Related]
40. Australian recommendations on perioperative use of disease-modifying anti-rheumatic drugs in people with inflammatory arthritis undergoing elective surgery.
Buchbinder R; Glennon V; Johnston RV; Brennan SE; Fong C; Edward May S; O'Neill S; Smitham P; Trevena L; Whittaker G; Wluka A; Whittle SL
Intern Med J; 2023 Jul; 53(7):1248-1255. PubMed ID: 37067924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
